BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 26725920)

  • 1. Long-Term Safety of a Coordinated Delivery Tablet of Enteric-Coated Aspirin 325 mg and Immediate-Release Omeprazole 40 mg for Secondary Cardiovascular Disease Prevention in Patients at GI Risk.
    Goldstein JL; Whellan DJ; Scheiman JM; Cryer BL; Eisen GM; Lanas A; Fort JG
    Cardiovasc Ther; 2016 Apr; 34(2):59-66. PubMed ID: 26725920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PA32540 (a coordinated-delivery tablet of enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg) versus enteric-coated aspirin 325 mg alone in subjects at risk for aspirin-associated gastric ulcers: results of two 6-month, phase 3 studies.
    Whellan DJ; Goldstein JL; Cryer BL; Eisen GM; Lanas A; Miller AB; Scheiman JM; Fort JG; Zhang Y; O'Connor C
    Am Heart J; 2014 Oct; 168(4):495-502.e4. PubMed ID: 25262259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of PA32540 in Protecting the Gastric Layer While Providing Secondary Prevention for Coronary Artery Disease.
    Kagolanu D; Sayedy N; Haseeb S; Shah S; Lam P; Munnangi S; Viswanathan P; Stephenson K
    Am J Cardiol; 2017 Oct; 120(7):1118-1121. PubMed ID: 28803655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The budget impact of using enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg to prevent recurrent cardiovascular events.
    Zhang W; Han Y; Fort JG; Schofield D; Tursi JP
    J Med Econ; 2017 Jun; 20(6):592-598. PubMed ID: 28145783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aspirin Use in Secondary Cardiovascular Protection and the Development of Aspirin-Associated Erosions and Ulcers.
    Goldstein JL; Scheiman JM; Fort JG; Whellan DJ
    J Cardiovasc Pharmacol; 2016 Aug; 68(2):121-6. PubMed ID: 27002280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel.
    Gurbel PA; Bliden KP; Fort JG; Jeong YH; Shuldiner A; Chai S; Gesheff T; Antonino M; Gesheff M; Zhang Y; Tantry US
    Am Heart J; 2013 Feb; 165(2):176-82. PubMed ID: 23351820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PA tablets: investigational compounds combining aspirin and omeprazole for cardioprotection.
    Bliden KP; Brener M; Gesheff MG; Franzese CJ; Tabrizchi A; Tantry U; Gurbel PA
    Future Cardiol; 2013 Nov; 9(6):785-97. PubMed ID: 24180537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aspirin and omeprazole for secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers.
    García-Rayado G; Sostres C; Lanas A
    Expert Rev Clin Pharmacol; 2017 Aug; 10(8):875-888. PubMed ID: 28463532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of pharmacokinetic and pharmacodynamic modeling and safety of proton pump inhibitors and aspirin.
    Gesheff MG; Franzese CJ; Bliden KP; Contino CJ; Rafeedheen R; Tantry US; Gurbel PA
    Expert Rev Clin Pharmacol; 2014 Sep; 7(5):645-53. PubMed ID: 25098174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg) or enteric-coated aspirin 325 mg + enteric-coated omeprazole 40 mg - a randomised, phase 1, crossover study.
    Miner PB; Fort JG; Zhang Y
    Aliment Pharmacol Ther; 2013 Jul; 38(1):62-71. PubMed ID: 23692061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy.
    Vaduganathan M; Bhatt DL; Cryer BL; Liu Y; Hsieh WH; Doros G; Cohen M; Lanas A; Schnitzer TJ; Shook TL; Lapuerta P; Goldsmith MA; Laine L; Cannon CP;
    J Am Coll Cardiol; 2016 Apr; 67(14):1661-71. PubMed ID: 27012778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety of naproxen and esomeprazole magnesium fixed-dose combination: phase III study in patients at risk for NSAID-associated gastric ulcers.
    Sostek MB; Fort JG; Estborn L; Vikman K
    Curr Med Res Opin; 2011 Apr; 27(4):847-54. PubMed ID: 21319944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similar Efficacy of Proton-Pump Inhibitors vs H2-Receptor Antagonists in Reducing Risk of Upper Gastrointestinal Bleeding or Ulcers in High-Risk Users of Low-Dose Aspirin.
    Chan FK; Kyaw M; Tanigawa T; Higuchi K; Fujimoto K; Cheong PK; Lee V; Kinoshita Y; Naito Y; Watanabe T; Ching JY; Lam K; Lo A; Chan H; Lui R; Tang RS; Sakata Y; Tse YK; Takeuchi T; Handa O; Nebiki H; Wu JC; Abe T; Mishiro T; Ng SC; Arakawa T
    Gastroenterology; 2017 Jan; 152(1):105-110.e1. PubMed ID: 27641510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Strategy to manage low dose aspirin-induced gastrointestinal injury].
    Hiraishi H; Maeda M; Sasai T; Kanke K; Shimada T
    Nihon Rinsho; 2011 Feb; 69(2):369-75. PubMed ID: 21387691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
    Ikeda Y; Shimada K; Teramoto T; Uchiyama S; Yamazaki T; Oikawa S; Sugawara M; Ando K; Murata M; Yokoyama K; Ishizuka N
    JAMA; 2014 Dec; 312(23):2510-20. PubMed ID: 25401325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of the antiplatelet combination aspirin (acetylsalicylic acid) plus extended-release dipyridamole are not altered by coadministration with the potent CYP2C19 inhibitor omeprazole.
    Offman E; Schobelock MJ; Brickl R; VanderMaelen CP; Ehrlich J; Eisert W
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):113-20. PubMed ID: 23532686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial.
    Sung JJ; Lau JY; Ching JY; Wu JC; Lee YT; Chiu PW; Leung VK; Wong VW; Chan FK
    Ann Intern Med; 2010 Jan; 152(1):1-9. PubMed ID: 19949136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Yosprala: A Fixed Dose Combination of Aspirin and Omeprazole.
    Veltri KT
    Cardiol Rev; 2018; 26(1):50-53. PubMed ID: 29045287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omeprazole taken once every other day can effectively prevent aspirin-induced gastrointestinal mucosal damage in rats.
    Weng J; Song Y; Kuai D; Dai W; Yao Y; Xu W; Li Y; Fan L; Xu B
    BMC Gastroenterol; 2024 May; 24(1):187. PubMed ID: 38811868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding.
    Hsiao FY; Tsai YW; Huang WF; Wen YW; Chen PF; Chang PY; Kuo KN
    Clin Ther; 2009 Sep; 31(9):2038-47. PubMed ID: 19843493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.